• Je něco špatně v tomto záznamu ?

Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors

L. Boublikova, V. Bakardjieva-Mihaylova, K. Skvarova Kramarzova, D. Kuzilkova, A. Dobiasova, K. Fiser, J. Stuchly, M. Kotrova, T. Buchler, P. Dusek, M. Grega, B. Rosova, Z. Vernerova, P. Klezl, M. Pesl, R. Zachoval, M. Krolupper, M. Kubecova, V....

. 2016 ; 376 (2) : 367-376. [pub] 20160413

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013945

Grantová podpora
NT12414 MZ0 CEP - Centrální evidence projektů

PURPOSE: Wilms tumor gene 1 (WT1), a zinc-finger transcription factor essential for testis development and function, along with other genes, was investigated for their role in the pathogenesis of testicular germ cell tumors (TGCT). METHODS: In total, 284 TGCT and 100 control samples were investigated, including qPCR for WT1 expression and BRAF mutation, p53 immunohistochemistry detection, and massively parallel amplicon sequencing. RESULTS: WT1 was significantly (p < 0.0001) under-expressed in TGCT, with an increased ratio of exon 5-lacking isoforms, reaching low levels in chemo-naïve relapsed TGCT patients vs. high levels in chemotherapy-pretreated relapsed patients. BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors. Of 9 selected TGCT-linked genes, RAS/BRAF and WT1 mutations were frequent while significant TP53 and KIT variants were not detected (p = 0.0003). CONCLUSIONS: WT1 has been identified as a novel factor involved in TGCT pathogenesis, with a potential prognostic impact. Distinct biologic nature of the two types of relapses occurring in TGCT has been demonstrated. Differential mutation rate of the key TGCT-related genes has been documented.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013945
003      
CZ-PrNML
005      
20191113090843.0
007      
ta
008      
170413s2016 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.canlet.2016.04.016 $2 doi
035    __
$a (PubMed)27085458
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Boublíková, Ludmila $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. Electronic address: ludmila.boublikova@lfmotol.cuni.cz. $7 jn20010310080
245    10
$a Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors / $c L. Boublikova, V. Bakardjieva-Mihaylova, K. Skvarova Kramarzova, D. Kuzilkova, A. Dobiasova, K. Fiser, J. Stuchly, M. Kotrova, T. Buchler, P. Dusek, M. Grega, B. Rosova, Z. Vernerova, P. Klezl, M. Pesl, R. Zachoval, M. Krolupper, M. Kubecova, V. Stahalova, J. Abrahamova, M. Babjuk, R. Kodet, J. Trka,
520    9_
$a PURPOSE: Wilms tumor gene 1 (WT1), a zinc-finger transcription factor essential for testis development and function, along with other genes, was investigated for their role in the pathogenesis of testicular germ cell tumors (TGCT). METHODS: In total, 284 TGCT and 100 control samples were investigated, including qPCR for WT1 expression and BRAF mutation, p53 immunohistochemistry detection, and massively parallel amplicon sequencing. RESULTS: WT1 was significantly (p < 0.0001) under-expressed in TGCT, with an increased ratio of exon 5-lacking isoforms, reaching low levels in chemo-naïve relapsed TGCT patients vs. high levels in chemotherapy-pretreated relapsed patients. BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors. Of 9 selected TGCT-linked genes, RAS/BRAF and WT1 mutations were frequent while significant TP53 and KIT variants were not detected (p = 0.0003). CONCLUSIONS: WT1 has been identified as a novel factor involved in TGCT pathogenesis, with a potential prognostic impact. Distinct biologic nature of the two types of relapses occurring in TGCT has been demonstrated. Differential mutation rate of the key TGCT-related genes has been documented.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a mutační analýza DNA $x metody $7 D004252
650    _2
$a down regulace $7 D015536
650    _2
$a studie proveditelnosti $7 D005240
650    12
$a geny ras $7 D011905
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a germinální a embryonální nádory $x enzymologie $x genetika $x patologie $7 D009373
650    _2
$a fenotyp $7 D010641
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    _2
$a protoonkogenní proteiny c-kit $x genetika $7 D019009
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a testikulární nádory $x enzymologie $x genetika $x patologie $7 D013736
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
650    _2
$a proteiny WT1 $x genetika $7 D025721
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bakardjieva-Mihaylova, Violeta $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0212934
700    1_
$a Škvárová Kramarzová, Karolína $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0128636
700    1_
$a Kuzilkova, D $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Dobiasova, A $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fišer, Karel $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0116772
700    1_
$a Stuchlý, Jan $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0143777
700    1_
$a Kotrová, Michaela $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0209776
700    1_
$a Büchler, Tomáš, $u Department of Oncology, 1st Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. $d 1974- $7 xx0096851
700    1_
$a Dusek, P $u Department of Urology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Grega, Marek $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $7 xx0209713
700    1_
$a Rosová, Blanka $u Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic. $7 xx0121469
700    1_
$a Vernerová, Zdenka, $u Department of Pathology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. $d 1960-2020 $7 jo2002104672
700    1_
$a Klézl, Petr, $u Department of Urology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. $d 1968- $7 xx0081732
700    1_
$a Pešl, Michal, $u Department of Urology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. $d 1975- $7 xx0081957
700    1_
$a Zachoval, Roman, $u Department of Urology, Thomayer Hospital, Prague, Czech Republic. $d 1967- $7 mzk2004248672
700    1_
$a Krolupper, Marek $7 xx0241909 $u Department of Urology, Na Bulovce Hospital, Prague, Czech Republic.
700    1_
$a Kubecová, Martina $u Department of Oncology and Radiotherapy, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. $7 xx0083618
700    1_
$a Stáhalová, Vladimíra, $u Institute of Radiotherapy and Oncology, 1st Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic. $d 1950- $7 mzk2008459023
700    1_
$a Abrahámová, Jitka $u Department of Oncology, 1st Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic. $7 jn20001103578
700    1_
$a Babjuk, Marko, $u Department of Urology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $d 1961- $7 jn20020716353
700    1_
$a Kodet, Roman, $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $d 1953- $7 nlk19990073380
700    1_
$a Trka, Jan, $u Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic. $d 1966- $7 xx0036261
773    0_
$w MED00001044 $t Cancer letters $x 1872-7980 $g Roč. 376, č. 2 (2016), s. 367-376
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27085458 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20191113091120 $b ABA008
999    __
$a ok $b bmc $g 1200410 $s 974723
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 376 $c 2 $d 367-376 $e 20160413 $i 1872-7980 $m Cancer letters $n Cancer Lett $x MED00001044
GRA    __
$a NT12414 $p MZ0
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace